- Healthcare 150
- Posts
- The Hospital Performance Problem No One Agrees On
The Hospital Performance Problem No One Agrees On
Hospital leaders split on the industry’s biggest performance gap, the FDA clears a new oncology treatment, and Toscafund makes a $1B+ take private bet.
Gaston Brizuela Bosio
September 10, 2026
Good morning, ! This week we’re diving into the performance gaps in hospitals, FDA approval of a new oncology treatment, and Toscafunds $1B+ take-private.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here.
— The Healthcare150 Team
MICROSURVEY
Hospital Performance Gaps Depend on Who You Ask
Hospital leaders agree performance is under pressure, but they disagree sharply on where the biggest problem sits.
Among clinical leaders, 54% identify workforce productivity and staffing as the largest gap, more than double the share citing financial performance or patient throughput, both at 23%. Financial and risk leaders are more balanced, with 42% pointing to workforce issues and 37% to financial performance.
The picture flips for technology and operational executives. 56% of IT and data leaders identify financial performance and revenue cycle as the biggest gap, while only 11% prioritize throughput. Operational leaders also lean toward financial performance at 50%, with workforce and throughput tied at 25%.
Why it matters: The constraint may not be a single hospital wide problem. It may be fragmented accountability. Investment priorities will increasingly depend on which executive owns the budget, making cross functional alignment critical before systems commit capital to workforce, revenue cycle, or capacity initiatives. (Read Full Article)
PRESENTED BY DYNAMO SOFTWARE
Are You Asking the Right Questions About Your FinTech Stack?
Features are only part of the equation. Security gaps, hidden fees, weak integrations, and limited scalability can turn the wrong technology decision into a costly one.
Dynamo Software’s FinTech Due Diligence Checklist gives alternative investment firms a practical framework focusing on six essential areas for evaluating technology providers. The checklist covers everything from AI and system compatibility to security, pricing, and client support.
Built on 20+ years serving the alternatives industry, the checklist helps teams pressure-test their current diligence process and uncover potential blind spots before committing to a provider.
HEADLINE OF THE WEEK
ctDNA Moves From Monitoring Tool to Treatment Trigger
The FDA’s accelerated approval of Etcamah marks a meaningful shift in oncology. For the first time, a cancer treatment can be changed based on a resistance mutation detected in circulating tumor DNA before imaging confirms disease progression.
That changes the treatment clock.
In HR-positive, HER2-negative advanced breast cancer, fewer than 5% of patients have an ESR1 mutation at diagnosis, but nearly 40% develop one after progression on an aromatase inhibitor. Under the new pathway, clinicians can identify that resistance earlier through the Guardant360 CDx assay and switch therapy before radiographic deterioration.
The clinical signal is substantial. Median progression-free survival reached 16 months with camizestrant plus a CDK4/6 inhibitor versus 9.2 months for continued aromatase inhibitor therapy.
Why it matters: If confirmatory studies validate clinical benefit, ctDNA could evolve from a surveillance technology into a recurring treatment decision layer. That would expand the strategic value of liquid biopsy, companion diagnostics, and therapies designed around molecular resistance rather than visible progression. (More)
DEAL OF THE WEEK
Toscafund’s £1.03B Healthcare Take-Private
Toscafund Asset Management agreed to acquire Spire Healthcare for roughly £1.03B, taking one of the U.K.’s largest private hospital operators off the London Stock Exchange.
The deal puts a sizable private capital bet behind a healthcare model benefiting from structural pressure on the U.K.’s public health system. Spire operates a nationwide network of private hospitals and clinics, giving its new owners exposure to growing demand from patients, insurers and the NHS for additional healthcare capacity.
For PE, the appeal goes beyond defensive healthcare demand. Hospital platforms combine hard-to-replicate physical infrastructure, regulatory barriers and established clinical networks—characteristics that can create meaningful barriers to entry despite their capital intensity.
The PE takeaway: As sponsors hunt for durable cash flows, healthcare infrastructure remains difficult to ignore. Toscafund is betting £1.03B that constrained capacity can make private hospitals an increasingly valuable part of the U.K. healthcare system.
DEAL TRACKER
Undisclosed | TPG → Optum Health Operations
TPG acquired a stake in certain Optum Health operations in Florida from UnitedHealth, extending private equity’s push into healthcare services as strategic players continue to reshape their care-delivery portfolios. Read more
Undisclosed | Labcorp → MLM Medical Labs
Labcorp acquired Great Point Partners- and Migration Capital-backed MLM Medical Labs, expanding its central and specialty laboratory footprint across the U.S., Germany and South Africa and delivering a healthcare sponsor exit to a strategic buyer. Read more
Undisclosed | H.I.G. Capital → Outcomes One
H.I.G. Capital acquired Outcomes One, a pharmacy technology and clinical services platform whose network reaches roughly 85% of U.S. pharmacies, giving the sponsor significant scale in tech-enabled pharmacy and clinical intervention services. Read more
Undisclosed | Iron Path-backed VION Biosciences → Prolytix
Iron Path Capital-backed VION Biosciences acquired Prolytix, its sixth acquisition since 2023, expanding its bioanalytical testing capabilities and continuing a buy-and-build strategy across outsourced life sciences services. Read more
REGIONAL FOCUS
India’s AI Opportunity Starts in the Back Office
India’s healthcare AI story is moving from experimentation to deployment—but the first winners may look less like futuristic diagnostics and more like workflow software.
Bain and HealthQuad’s analysis maps AI use cases by value, deployability, and trust. The “scale now” bucket is dominated by appointment and preclinical triage, OPD/clinical consult support, claims and billing, and finance, HR, and procurement. Meanwhile, diagnostics, inpatient care, and other clinically intensive applications remain further from scaled deployment.
The distinction matters. Administrative workflows offer high potential value with fewer clinical-risk and trust barriers, giving providers a clearer path from AI pilots to measurable ROI. Diagnostics may ultimately carry greater clinical upside, but scaling requires more investment, validation, and human oversight.
The bottom line: India’s near-term AI opportunity is an efficiency play before it becomes a clinical one. For investors, the sweet spot is likely companies that can plug into existing hospital workflows, prove savings quickly, and build the data and trust required to move deeper into care delivery.
